• Gilmour Space Technologies

  Participated · Equity · Jan 2026

  Gilmour Space Technologies is a Queensland-based launch vehicle and satellite manufacturer focused on providing domestic and international access to space. Its core product is the Eris small launch vehicle, which completed an inaugural flight in July but failed 14 seconds after liftoff due to an engine issue the team is now addressing. The company also manufactures spacecraft and placed its first satellite, ElaraSat, into orbit via a SpaceX rideshare mission in June 2025. Fueled by rising demand for sovereign launch capabilities, the firm intends to scale production of both rockets and satellites while preparing a second Eris launch attempt targeted for 2026. Management reports a workforce of more than 220 employees and plans to hire aggressively with new capital. The latest raise pushes Gilmour’s valuation above US$1 billion, making it Australia’s first space-technology “unicorn.”

• Moximed

  Participated · Series D · Aug 2024

  Moximed's core product is the MISHA Knee System, the first implantable shock absorber designed to reduce about 30% of peak force on the knee with each walking step to relieve pain and preserve function in patients with medial knee osteoarthritis. The implant is placed during an outpatient procedure and has been shown to alleviate pain, improve function, and in some patients delay the need for total knee replacement. The company emphasizes a decade-plus of clinical research and development behind the technology and positions MISHA for patients with mild-to-moderate OA who seek joint-preserving options. Moximed intends to use recent financing proceeds to accelerate U.S. commercialization, expand commercial infrastructure, and broaden patient and surgeon access. The company highlights growing market opportunity given osteoarthritis prevalence in the U.S. and the product's clinical value proposition. Moximed is based in Fremont, California. Moximed, based in Fremont, California, commercializes the Misha knee system — described as the world’s first implantable shock absorber for the knee. The Misha device is designed for implantation during an outpatient procedure to alleviate pain, improve function, enable early weight bearing, and potentially delay total knee replacement for patients with mild-to-moderate osteoarthritis. The company says the system can preserve the native knee and address a treatment gap between conservative care and joint replacement. Moximed will use proceeds from the financing to pursue regulatory approvals and to establish commercial infrastructure for Misha. Results from the company’s pivotal study are slated for presentation on Sept. 22, 2020 at the Orthopedic Summit (OSET) in Boston. The article reports a $40M financing and additional debt financing support from Runway Growth Capital. Moximed develops unicompartmental shock-absorbing implants (KineSpring and Atlas systems) that absorb excess joint load without bone cutting or bone removal. The company reports treatment durability established to nearly nine years on initial patients, and the Atlas System is CE-marked in Europe. Moximed has fully enrolled its FDA pivotal clinical study of the KineSpring System and is currently enrolling a US IDE study of the Atlas System. The Atlas System is designed to provide approximately 30 lbs of unloading, is placed subcutaneously, and aims to preserve future treatment options. Moximed intends to use recent financing to complete FDA approval and support early US commercialization amid strong patient and surgeon interest. The company is backed by venture investors including NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, Vertex Healthcare, Advent Life Sciences, and Future Fund. Moximed focuses on minimally invasive, joint‑preserving solutions for patients with knee osteoarthritis. Its core product is the KineSpring System, a subcutaneous joint‑unloading implant intended for pre‑arthroplasty patients who want to remain active. The KineSpring System is CE marked, available in major European markets, investigational in the U.S., and has been implanted in over 1,000 cases worldwide. The company announced a financing to support efforts to obtain FDA approval for KineSpring and to grow commercial sales in Europe. Moximed is backed by venture investors including Vertex Venture Holdings, New Enterprise Associates, Gilde Healthcare Partners, Morgenthaler Ventures, and GBS Venture Partners. Management cites clinical evidence from its GOAL Study and strong patient interest in joint‑preserving treatments.

• GRACIA.AI

  Participated · Seed · Jun 2024

  Gracia AI is a London-based startup that has built what it claims is the world’s first production-ready, end-to-end platform for 4D Gaussian Splatting volumetric video. Its cloud-accelerated system handles the entire workflow—from raw capture through processing, editing, timeline control, and creative manipulation—delivering ready-to-use 4DGS assets. The offering includes a full studio environment plus dedicated Unity and Unreal Engine plugins, enabling seamless integration into XR, VFX, film, advertising, and gaming pipelines. The company also supports WebGPU-based 2D playback on Mac and web for broader accessibility. By providing a complete tech stack, Gracia AI aims to make 4DGS content practical for real-world production workflows and next-generation creative tools. The recent capital injection will be used to expand operations and accelerate product development. Founders Andrey Volodin and Georgii Vysotskii lead the venture, which positions itself at the intersection of volumetric video, cloud processing, and creative software.

• PlaqueTec

  Participated · Equity · May 2024

  PlaqueTec develops intracoronary liquid biopsy technology and operates BioCarta, a high-resolution cardiovascular data lake that captures proteomic biomarkers directly at sites of plaque formation. Its BIOPATTERN trial generates the platform’s proteomic and clinical data by sampling coronary concentration gradients to identify inflammation-related biomarkers and disease drivers. The company has leveraged its dataset to identify several potential therapeutic targets in subgroups of coronary artery disease patients. PlaqueTec is engaging with pharmaceutical and biotech partners interested in using its data for drug development and patient stratification. The recent $5 million financing will fund continued data collection, platform development, and partnership efforts to establish BioCarta as a foundational asset in cardiovascular research and precision medicine.

• Runes DEX

  Participated · Seed · Apr 2024

  Runes DEX is the first automated market maker (AMM) for runes on the Bitcoin blockchain, enabling the launch and trading of meme-based tokens and providing liquidity solutions and farming rewards. The platform includes a "Meme Casino" feature to integrate meme tokens and diversify offerings. CEO King of Runes said the company aims to set the standard for liquidity and trading solutions on Bitcoin and to democratize access to financial tools. Runes DEX plans a Token Generation Event on April 20, 2024, coinciding with the Bitcoin halving, and will run a public token presale ahead of that date. The company intends to use proceeds to expand technical infrastructure, improve user interface designs, and broaden market reach in advance of its anticipated "420 Launch".

No current team members are available.